We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chemours (CC) Up 2.9% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Chemours (CC - Free Report) . Shares have added about 2.9% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Chemours due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Chemours’ Q4 Earnings Beat, Revenue Miss Estimates
Chemours reported a net loss of $18 million or 12 cents per share in fourth-quarter 2023 compared with the year-ago quarter's loss of $97 million or 65 cents.
Barring one-time items, earnings came in at 31 cents per share. The metric beat the Zacks Consensus Estimate of 29 cents.
In the fourth quarter, the company reported net sales of $1,361 million, reflecting a 1.7% increase compared to the previous year. However, it fell short of the Zacks Consensus Estimate of $1,370.5 million. The growth in sales was primarily attributed to a 7% rise in Titanium Technologies and a significant 17% increase in the Thermal & Specialized Solutions Segment. These gains were partially offset by a 15% decline in the Advanced Performance Materials unit.
Adjusted EBITDA surged by 47% year over year to reach $176 million for the quarter. This increase was primarily propelled by healthy demand within the Thermal & Specialized Solutions Segment, as well as lower input costs across Chemours’ businesses. Additionally, the implementation of the Titanium Technologies Transformation Plan contributed to operating expense savings, further enhancing the company’s profitability.
Segment Highlights
The Titanium Technologies division recorded revenues of $651 million in the quarter, marking a 7% increase compared to the previous year. This surpassed our estimate of $624.2 million. The rise in net sales was fueled by a 12% surge in volume and a 1% currency tailwind, partially offset by a 6% decline in price. Increased demand across all regions except North America drove the volume growth, while contractual price increases partially mitigated price declines in market-exposed channels.
In the Thermal & Specialized Solutions segment, revenues saw a 17% year-over-year increase, reaching $374 million in the reported quarter, though it fell short of our estimate of $440 million. The boost in net sales was attributed to a 10% volume increase, a 6% price increase, and a 1% currency tailwind. Volume growth spanned across the portfolio, excluding legacy refrigerant products. At the same time, price increases were driven by pricing actions in legacy hydrofluorocarbons and various product portfolios, including Refrigerants and Foam, Propellants, and Other Products.
Revenues in the Advanced Performance Materials unit amounted to $325 million, marking a decline of approximately 15% year over year. Despite surpassing our estimate of $309.4 million, this decline was primarily driven by an 18% drop in volume, partially offset by a 2% increase in price, with a 1% currency tailwind. The decrease in volume was primarily attributed to soft demand in APM's Advanced Materials portfolio, which caters to economically sensitive end markets. However, the price increase was sustained by robust pricing in high-value end markets within APM's Performance Solutions portfolio, including advanced electronics and clean energy.
FY23 Results
For the full year 2023, Chemours reported net sales of $6,027 million, reflecting an 11% decline compared to the previous year. Adjusted Net Income stood at $425 million, a notable decrease from $738 million in the prior year. This resulted in an adjusted earnings per share of $2.82, down from $4.66 per share in the previous year. Adjusted EBITDA amounted to $1,014 million, compared to $1,361 million in the prior year.
Financials
Chemours ended the quarter with cash and cash equivalents of $1,203 million, up around 9% year over year. Long-term debt was $3,987 million, up nearly 11% year over year.
Cash provided by operating activities was $482 million in the reported quarter, up $321 million from the prior-year quarter.
Outlook
In the first quarter of 2024, the company forecasts that consolidated net sales will remain relatively stable or experience a slight decline compared to the previous quarter, while consolidated adjusted EBITDA is anticipated to decrease by approximately 10% compared with fourth-quarter 2023 levels. Operating cash flow is expected to see an outflow of about $400 million in the quarter, mainly due to seasonal fluctuations in working capital. In comparison, capital expenditures are projected to be around $100 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
The consensus estimate has shifted -19.18% due to these changes.
VGM Scores
Currently, Chemours has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Chemours has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Chemours (CC) Up 2.9% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Chemours (CC - Free Report) . Shares have added about 2.9% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Chemours due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Chemours’ Q4 Earnings Beat, Revenue Miss Estimates
Chemours reported a net loss of $18 million or 12 cents per share in fourth-quarter 2023 compared with the year-ago quarter's loss of $97 million or 65 cents.
Barring one-time items, earnings came in at 31 cents per share. The metric beat the Zacks Consensus Estimate of 29 cents.
In the fourth quarter, the company reported net sales of $1,361 million, reflecting a 1.7% increase compared to the previous year. However, it fell short of the Zacks Consensus Estimate of $1,370.5 million. The growth in sales was primarily attributed to a 7% rise in Titanium Technologies and a significant 17% increase in the Thermal & Specialized Solutions Segment. These gains were partially offset by a 15% decline in the Advanced Performance Materials unit.
Adjusted EBITDA surged by 47% year over year to reach $176 million for the quarter. This increase was primarily propelled by healthy demand within the Thermal & Specialized Solutions Segment, as well as lower input costs across Chemours’ businesses. Additionally, the implementation of the Titanium Technologies Transformation Plan contributed to operating expense savings, further enhancing the company’s profitability.
Segment Highlights
The Titanium Technologies division recorded revenues of $651 million in the quarter, marking a 7% increase compared to the previous year. This surpassed our estimate of $624.2 million. The rise in net sales was fueled by a 12% surge in volume and a 1% currency tailwind, partially offset by a 6% decline in price. Increased demand across all regions except North America drove the volume growth, while contractual price increases partially mitigated price declines in market-exposed channels.
In the Thermal & Specialized Solutions segment, revenues saw a 17% year-over-year increase, reaching $374 million in the reported quarter, though it fell short of our estimate of $440 million. The boost in net sales was attributed to a 10% volume increase, a 6% price increase, and a 1% currency tailwind. Volume growth spanned across the portfolio, excluding legacy refrigerant products. At the same time, price increases were driven by pricing actions in legacy hydrofluorocarbons and various product portfolios, including Refrigerants and Foam, Propellants, and Other Products.
Revenues in the Advanced Performance Materials unit amounted to $325 million, marking a decline of approximately 15% year over year. Despite surpassing our estimate of $309.4 million, this decline was primarily driven by an 18% drop in volume, partially offset by a 2% increase in price, with a 1% currency tailwind. The decrease in volume was primarily attributed to soft demand in APM's Advanced Materials portfolio, which caters to economically sensitive end markets. However, the price increase was sustained by robust pricing in high-value end markets within APM's Performance Solutions portfolio, including advanced electronics and clean energy.
FY23 Results
For the full year 2023, Chemours reported net sales of $6,027 million, reflecting an 11% decline compared to the previous year. Adjusted Net Income stood at $425 million, a notable decrease from $738 million in the prior year. This resulted in an adjusted earnings per share of $2.82, down from $4.66 per share in the previous year. Adjusted EBITDA amounted to $1,014 million, compared to $1,361 million in the prior year.
Financials
Chemours ended the quarter with cash and cash equivalents of $1,203 million, up around 9% year over year. Long-term debt was $3,987 million, up nearly 11% year over year.
Cash provided by operating activities was $482 million in the reported quarter, up $321 million from the prior-year quarter.
Outlook
In the first quarter of 2024, the company forecasts that consolidated net sales will remain relatively stable or experience a slight decline compared to the previous quarter, while consolidated adjusted EBITDA is anticipated to decrease by approximately 10% compared with fourth-quarter 2023 levels. Operating cash flow is expected to see an outflow of about $400 million in the quarter, mainly due to seasonal fluctuations in working capital. In comparison, capital expenditures are projected to be around $100 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
The consensus estimate has shifted -19.18% due to these changes.
VGM Scores
Currently, Chemours has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Chemours has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.